development of disease between women in the placebo and those in the vaccine group continued to widen over the three years. This means that the precision of the data continued to increase; even more young women than initially thought could benefit from Gardasil®," comments Professor Margaret Stanley of the University of Cambridge, UK.

The virus types 6, 11, 16 and 18 directly targeted by Gardasil® cause the vast majority of genital Human Papillomavirus diseases. It is estimated that among Human Papillomavirus diseases in Europe, they cause 75% of cervical cancer, 95% of vulvar and vaginal cancers, , 70% of pre-cancerous (CIN2/3) , and 50% of potentially pre-cancerous cervical lesions (CIN1) , 80% of pre-cancerous vulvar (VIN2/3) and vaginal lesions (VaIN2/3)5,6, , , and 90% of genital warts. ,

In FUTURE I, after three years of follow up, Gardasil® prevented 100% of Human Papillomavirus types 6-, 11-, 16- and 18-related pre-cancerous and potentially pre-cancerous cervical lesions (CIN1-3); there was no case observed in the vaccine group compared to 65 cases in the placebo group. Gardasil® prevented also 100% of types 6-, 11-, 16- and 18-related pre-cancerous and potentially pre-cancerous vulvar and vaginal lesions (VIN1-3 and VaIN1-3) and genital warts; no case was observed in the vaccine group compared to 60 cases in the placebo group.b)

In FUTURE* II, after three years of follow up, Gardasil® prevented 98% of pre-cancerous cervical lesions (CIN†2/3) associated with Human Papillomavirus types 16 and 18; one case of CIN3 was observed in the vaccine group compared to 42 cases in the placebo group. b) In a combined analysis, including almost 17,000 women and recently presented at the 5th International Conference on Cervical Cancer (ICCC) in Venice, Gardasil® prevented 99% of pre-cancerous cervical lesions (CIN†2/3) associated with Human Papillomavirus types 16 and 18; 85 cases were obse
'"/>




Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Data Published in The Lancet Show Gardasil was 100 Percent Effective in Preventing High-Grade Vulvar and Vaginal Lesions Caused by HPV Types 16 and 18
2. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
5. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
6. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
7. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
8. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
9. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
10. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
11. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer